(NBIX) Neurocrine Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64125C1099

Movement, Endocrine, Psychiatric, Adrenal, Gynecology

Biotechnology
Market Cap in USD: 14,019m

IPO / Inception: 1996-05-23
Return 12m vs S&P 500: -21.4%

EPS (Earnings per Share)

EPS CAGR: -3.90%
EPS Trend: 46.7%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 28.32%
Rev. Trend: 97.8%

Last SUE: 2.77
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	33.8%
Value at Risk 5%th	47.6%
Relative Tail Risk	-14.43%

Reward TTM
Sharpe Ratio	0.03
Alpha	-18.30
CAGR/Max DD	0.18

Character TTM
Hurst Exponent	0.463
Beta	0.850
Beta Downside	0.794

Drawdowns 3y
Max DD	42.89%
Mean DD	10.56%
Median DD	8.09%

Description: NBIX Neurocrine Biosciences January 02, 2026

Neurocrine Biosciences (NASDAQ: NBIX) focuses on developing and commercializing drugs for neurological, neuroendocrine, and neuropsychiatric disorders, with a portfolio that includes FDA-approved products such as INGREZZA (tardive dyskinesia), ALKINDI (adrenal insufficiency), Orilissa (endometriosis), and Oriahnn (uterine fibroids). The company also maintains a pipeline of CNS-focused candidates (e.g., valbenazine for dyskinetic cerebral palsy, Osavampator for treatment-resistant depression) and collaborates with partners like Takeda, AbbVie, and Voyager Therapeutics.

Key recent metrics (Q4 2023): revenue ≈ $274 million, driven primarily by INGREZZA and ALKINDI; net income ≈ $71 million; cash and equivalents ≈ $1.2 billion, providing runway for late-stage trials. The valbenazine franchise contributed roughly $140 million in 2023, and the company’s R&D spend was about 16 % of revenue, reflecting a high-risk, high-reward pipeline strategy.

Sector drivers that materially affect NBIX’s outlook include: (1) the growing prevalence of rare and chronic CNS disorders in an aging population, which expands the addressable market; (2) heightened regulatory scrutiny and the need for robust Phase III data, which increases binary outcome risk; and (3) the biotech financing environment, where elevated interest rates have compressed valuation multiples, making cash-rich companies with late-stage assets relatively more attractive.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of NBIX’s valuation metrics.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (428.0m TTM) > 0 and > 6% of Revenue (6% = 161.0m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 1.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.67% (prev 64.51%; Δ -7.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 636.8m > Net Income 428.0m (YES >=105%, WARN >=100%)

Net Debt (88.2m) to EBITDA (665.4m) ratio: 0.13 <= 3.0 (WARN <= 3.5)

Current Ratio 3.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (102.5m) change vs 12m ago -1.73% (target <= -2.0% for YES)

Gross Margin 98.37% (prev 98.52%; Δ -0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 68.78% (prev 63.45%; Δ 5.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.02 (EBITDA TTM 665.4m / Interest Expense TTM 126.6m) >= 6 (WARN >= 3)

Altman Z'' 3.91

(A) 0.36 = (Total Current Assets 2.16b - Total Current Liabilities 638.0m) / Total Assets 4.27b

(B) 0.07 = Retained Earnings (Balance) 294.0m / Total Assets 4.27b

(D) 0.24 = Book Value of Equity 307.3m / Total Liabilities 1.26b

Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.53

1. Piotroski 6.50pt

2. FCF Yield 4.45%

3. FCF Margin 22.11%

4. Debt/Equity 0.14

5. Debt/Ebitda 0.13

6. ROIC - WACC (= 7.46)%

7. RoE 15.82%

8. Rev. Trend 97.76%

9. EPS Trend 46.65%

What is the price of NBIX shares?

As of January 12, 2026, the stock is trading at USD 135.79 with a total of 1,419,297 shares traded.
Over the past week, the price has changed by -0.15%, over one month by -12.25%, over three months by -1.14% and over the past year by -5.06%.

Is NBIX a buy, sell or hold?

Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.

Strong Buy: 15
Buy: 7
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the NBIX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	179.7	32.3%
Analysts Target Price	179.7	32.3%
ValueRay Target Price	141.3	4.1%

NBIX Fundamental Data Overview January 05, 2026

P/E Trailing = 33.5561
P/E Forward = 19.685
P/S = 5.2256
P/B = 4.6673
P/EG = 0.2733
Beta = 0.274
Revenue TTM = 2.68b USD
EBIT TTM = 635.7m USD
EBITDA TTM = 665.4m USD
Long Term Debt = 428.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 428.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 88.2m USD (from netDebt column, last quarter)
Enterprise Value = 13.33b USD (14.02b + Debt 428.4m - CCE 1.11b)
Interest Coverage Ratio = 5.02 (Ebit TTM 635.7m / Interest Expense TTM 126.6m)
EV/FCF = 22.48x (Enterprise Value 13.33b / FCF TTM 593.1m)
FCF Yield = 4.45% (FCF TTM 593.1m / Enterprise Value 13.33b)
FCF Margin = 22.11% (FCF TTM 593.1m / Revenue TTM 2.68b)
Net Margin = 15.95% (Net Income TTM 428.0m / Revenue TTM 2.68b)
Gross Margin = 98.37% ((Revenue TTM 2.68b - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 98.24% (prev 98.36%)
Tobins Q-Ratio = 3.13 (Enterprise Value 13.33b / Total Assets 4.27b)
Interest Expense / Debt = 29.55% (Interest Expense 126.6m / Debt 428.4m)
Taxrate = 28.20% (82.3m / 291.8m)
NOPAT = 456.4m (EBIT 635.7m * (1 - 28.20%))
Current Ratio = 3.38 (Total Current Assets 2.16b / Total Current Liabilities 638.0m)
Debt / Equity = 0.14 (Debt 428.4m / totalStockholderEquity, last quarter 3.00b)
Debt / EBITDA = 0.13 (Net Debt 88.2m / EBITDA 665.4m)
Debt / FCF = 0.15 (Net Debt 88.2m / FCF TTM 593.1m)
Total Stockholder Equity = 2.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.97% (Net Income 428.0m / Total Assets 4.27b)
RoE = 15.82% (Net Income TTM 428.0m / Total Stockholder Equity 2.71b)
RoCE = 20.28% (EBIT 635.7m / Capital Employed (Equity 2.71b + L.T.Debt 428.4m))
RoIC = 16.87% (NOPAT 456.4m / Invested Capital 2.71b)
WACC = 9.41% (E(14.02b)/V(14.45b) * Re(9.05%) + D(428.4m)/V(14.45b) * Rd(29.55%) * (1-Tc(0.28)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF Debug] Terminal Value 76.82% ; FCFF base≈531.9m ; Y1≈656.1m ; Y5≈1.12b
Fair Price DCF = 146.2 (EV 14.66b - Net Debt 88.2m = Equity 14.58b / Shares 99.7m; r=9.41% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 46.65 | EPS CAGR: -3.90% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.76 | Revenue CAGR: 28.32% | SUE: 2.77 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.99 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=9.17 | Chg30d=+0.024 | Revisions Net=+0 | Growth EPS=+32.7% | Growth Revenue=+19.0%

Additional Sources for NBIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle